Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development

ILAR Journal

Volumn 55, Issue 1, 2014, Pages 100-118

  Knapp, Deborah W ^a,b   Ramos Vara, José A ^a   Moore, George E ^a   Dhawan, Deepika ^a   Bonney, Patty L ^a   Young, Kirsten E ^a  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

Author keywords

Animal model; Bladder cancer; Dog; Transitional cell carcinoma

Indexed keywords

ANIMAL; CARCINOMA, TRANSITIONAL CELL; DISEASE MODEL; DOG; DOG DISEASES; DRUG DEVELOPMENT; HUMAN; PATHOPHYSIOLOGY; PROCEDURES; SPECIES DIFFERENCE; URINARY BLADDER NEOPLASMS; VETERINARY;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; DRUG DISCOVERY; HUMANS; SPECIES SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 84902530553     PISSN: 10842020     EISSN: 19306180     Source Type: Journal    
DOI: 10.1093/ilar/ilu018     Document Type: Article

References (139)

1. Abbo AH, Jones DR, Masters AR, Stewart JC, Fourez L, Knapp DW. 2010. Phase 1 clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder. J Vet Intern Med 24:1124-1130.
2. Alavanja MC, Bonner MR. 2012. Occupational pesticide exposures and cancer risk: a review. J Toxicol Environ Health B Crit Rev 15:238-263.
3. Algra AM, Rothwell PM. 2012. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13:518-527.
4. Anderson CR, McNiel EA, Gillette EL, Powers BE, LaRue SM. 2002. Late complications of pelvic irradiation in 16 dogs. Vet Radiol Ultrasound 43:187-192.
5. Arantes-Rodrigues R, Colaço A, Pinto-Leite R, Oliveira PA. 2013. In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer. Anticancer Res 33:1273-1296.
6. Arnold EA, Childress MO, Fourez LM, Tan KM, Stewart JC, Bonney PL, Knapp DW. 2011. Phase II clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 25:1385-1390.
7. Backer LC, Grindem CB, Corbett WT, Cullins L, Hunter JL. 2001. Pet dogs as sentinels for environmental contamination. Sci Total Environ 274:161-169.
8. Baylin SB, Jones PA. 2011. A decade of exploring the cancer epigenome-Biological and translational implications. Nat Rev Cancer 11:726-734.
9. Besaratinia A, Cockburn M, Tommasi S. 2013. Alterations of DNA methylome in human bladder cancer. Epigenetics 8:1013-1022.
10. Blackburn AL, Berent AC, Weisse CW, Brown DC. 2013. Evaluation of outcome following urethral stent placement for the treatment of obstructive carcinoma of the urethra in dogs: 42 cases (2004-2008). J Am Vet Med Assoc 242:59-68.
11. Blumenreich MS, Yagoda A, Natale RB, Watson RC. 1982. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 50:435-438.
12. Boers D, Portengen L, Bueno-de-Mesquita HB, Heederik D, Vermeulen R. 2010. Cause-specific mortality of Dutch chlorophenoxy herbicide manufacturing workers. Occup Environ Med 67:24-31.
13. Boria PA, Glickman NW, Schmidt BR, Widmer WR, Mutsaers AJ, Adams LG, Snyder PW, DiBernardi L, de Gortari AE, Bonney PL, Knapp DW. 2005. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005 3:73-80.
14. Bryan JN, Keeler MR, Henry CJ, Bryan ME, Hahn AW, Caldwell CW. 2007. A population study of neutering status as a risk factor for canine prostate cancer. Prostate 67:1174-1181.
15. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. 2013. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234-241.
16. Cancer Genome Atlas Research Network. 2014. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature doi:10.1038/ nature12965.
17. Carvalho JC, Thomas DG, McHugh JB, Shah RB, Kunju LP. 2012. p63, CK7, PAX8 and INI-1: An optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumors of the renal collecting system. Histopathology 60:597-608.
18. Cekanova M, Uddin MJ, Bartges JW, Callens A, Legendre AM, Rathore K, Wright L, Carter A, Marnett LJ. 2013. Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo. Cancer Prev Res (Phila) 6:466-476.
19. Chang C, Lee SO, Yeh S, Chang TM. 2013. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast, and liver. Oncogene Oncogene doi:10.1038/ onc.2013.274.
20. Chen CH, Chen RJ. 2011. Prevalence of telomerase activity in human cancer. J Formos Med Assoc 110:275-289.
21. Cheng L, Davidson DD, Maclennan GT, Williamson SR, Zhang S, Koch MO, Montironi R, Lopez-Beltran A. 2010. The origins of urothelial carcinoma. Expert Rev Anticancer Ther 10:865-880.
22. Cheng L, MacLennan GT, Lopez-Beltrán A. 2012. Histologic grading of urothelial carcinoma: A reappraisal. Hum Pathol 43:2097-2108.
23. Childress MO, Adams LG, Ramos-Vara JA, Freeman LJ, He S, Constable PD, Knapp DW. 2011. Results of biopsy via transurethral cystoscopy and cystotomy for diagnosis of transitional cell carcinoma of the urinary bladder and urethra in dogs: 92 cases (2003-2008). J Am Vet Med Assoc 239:350-356.
24. Cooley DM, Beranek BC, Schlittler DL, Glickman NW, Glickman LT, Waters DJ. 2002. Endogenous gonadal hormone exposure and bone sarcoma risk. Cancer Epidemiol Biomarkers Prev 11:1434-1440.
25. de Brito Galvao JF, Kisseberth WC, Murahari S, Sutayatram S, Chew DJ, Inpanbutr N. 2012. Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines. Am J Vet Res 73:1262-1272.
26. de Groot DJ, de Vries EG, Groen HJ, de Jong S. 2007. Non-steroidal antiinflammatory drugs to potentiate chemotherapy effects: From lab to clinic. Crit Rev Oncol Hematol 61:52-69.
27. Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, Zheng R, Loman RA, Foster RS, Knapp DW. 2010. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther 9:1371-1377.
28. Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW. 2008. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 7:897-904.
29. Dhawan D, Ramos-Vara JA, Hahn NM, Waddell J, Olbricht GR, Zheng R, Stewart JC, Knapp DW. 2013. DNMT1: An emerging target in the treatment of invasive urinary bladder cancer. Urol Oncol 31:1761-1769.
30. Dhawan D, Ramos-Vara JA, Naughton JF, Cheng L, Low PS, Rothenbuhler R, Leamon CP, Parker N, Klein PJ, Vlahov IR, Reddy JA, Koch M, Murphy L, Fourez LM, Stewart JC, Knapp DW. 2013. Targeting folate receptors to treat invasive urinary bladder cancer. Cancer Res 73:875-884.
31. Dhawan D, Ramos-Vara JA, Stewart JC, Zheng R, Knapp DW. 2009. Canine invasive transitional cell carcinoma cell lines: In vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Urol Oncol 27:284-292.
32. Dietrich HG, Golka K. 2012. Bladder tumors and aromatic amines-Historical milestones from Ludwig Rehn to Wilhelm Hueper. Front Biosci (Elite Ed) 4:279-288.
33. Dill AL, Eberlin LS, Costa AB, Zheng C, Ifa DR, Cheng L, Masterson TA, Koch MO, Vitek O, Cooks RG. 2011. Multivariate statistical identification of human bladder carcinomas using ambient ionization imaging mass spectrometry. Chemistry 17:2897-2902.
34. Dill AL, Ifa DR, Manicke NE, Costa AB, Ramos-Vara JA, Knapp DW, Cooks RG. 2009. Lipid profiles of canine invasive transitional cell carcinoma of the urinary bladder and adjacent normal tissue by desorption electrospray ionization imaging mass spectrometry. Anal Chem 81:8758-8764.
35. Droller MJ. 2006. Epidemiology of bladder cancer. In: Lerner SP, Schoenberg MP, Sternberg CN, eds. Textbook of Bladder Cancer. Oxon UK: Taylor and Francis. p 3-12.
36. Eissa S, Motawi T, Badr S, Zaghlool A, Maher A. 2013. Evaluation of urinary human telomerase reverse transcriptase mRNA and scatter factor protein as urine markers for diagnosis of bladder cancer. Clin Lab 59:317-323.
37. Epstein JI. 2010. Diagnosis and classification of flat, papillary, and invasive urothelial carcinoma: the WHO/ISUP consensus. Int J Surg Pathol 18:106S-111S.
38. Epstein JI, Amin MB, Reuter VR, Mostofi FK. 1998. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22:1435-1448.
39. Felknor SA, Delclos GL. 2006. Occupational risk factors. In: Lerner SP, Schoenberg MP, Sternberg CN, eds. Textbook of Bladder Cancer. Oxon UK: Taylor and Francis. p 13-17.
40. Franekova M, Halasova E, Bukovska E, Luptak J, Dobrota D. 2008. Gene polymorphisms in bladder cancer. Urol Oncol 26:1-8.
41. Gakis G, Stenzl A. 2013. Gender-specific differences in muscle-invasive bladder cancer: The concept of sex steroid sensitivity. World J Urol 31:1059-1064.
42. Gamblin RM, Sagartz JE, Couto CG. 1997. Overexpression of p53 tumor suppressor protein in spontaneous arising neoplasms of dogs. Am J Vet Res 58:857-863.
43. George SK, Tovar-Sepulveda V, Shen SS, Jian W, Zhang Y, Hilsenbeck SG, Lerner SP, Smith CL. 2013. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol 6:244-255.
44. Glickman LT, Domanski LM, Maguire TG, Dubielzig RR, Churg A. 1983. Mesothelioma in pet dogs associated with exposure of their owners to asbestos. Environ Res 32:305-313.
45. Glickman LT, Raghavan M, Knapp DW, Bonney PL, Dawson MH. 2004. Herbicide exposure and the risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. J Am Vet Med Assoc 224:1290-1297.
46. Glickman LT, Schofer FS, McKee LJ, Reif JS, Goldschmidt MH. 1989. Epidemiologic study of insecticide exposures, obesity, and risk of bladder cancer in household dogs. J Toxicol Environ Health 28:407-414.
47. Haggag R, Farag K, Abu-Taleb F, Shamaa S, Zekri AR, Elbolkainy T, Khaled H. 2014. Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: A randomized phase II trial-an update. Med Oncol 31:811.
48. Hahn NM, Bonney PL, Dhawan D, Jones DR, Balch C, Guo Z, Hartman-Frey C, Fang F, Parker HG, Kwon EM, Ostrander EA, Nephew KP, Knapp DW. 2012. Subcutaneous 5-azacitidine treatment of naturally-occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. J Urol 187:302-309.
49. Higgins JPT, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, Marinelli RJ, Presti JC Jr, van de Rijn M, Brooks JD. 2007. Placental S100 (S100P) and GATA3: Markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 31:673-680.
50. Higuchi T, Burcham GN, Childress MO, Rohleder JJ, Bonney PL, Ramos-Vara JA, Knapp DW. 2013. Characterization and treatment of transitional cell carcinoma of the abdominal wall in dogs: 24 cases (1985-2010). J Am Vet Med Assoc. 242:499-506.
51. Hsu I, Chuang KL, Slavin S, Da J, Lim WX, Pang ST, O'Brien JH, Yeh S. 2013. Suppression of ERβ signaling via ERβ knockout or antagonist protects against bladder cancer development. Carcinogenesis 35:651-661.
52. Ismaili N, Amzerin M, Flechon A. 2011. Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol 4:35.
53. Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ, Mongan NP. 2013. Estrogen receptor-β expression and pharmacological targeting in bladder cancer. Oncol Rep 30:131-138.
54. Kelsey JL, Moore AS, Glickman LT. 1998. Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiol Rev 20:204-217.
55. Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, Fitzgerald SD, Gamble D, Ginn PE, Goldschmidt MH, Hendrick MJ, Howerth EW, Janovitz EB, Langohr I, Lenz SD, Lipscomb TP, Miller MA, Misdorp W, Moroff S, Mullaney TP, Neyens I, O'Toole D, Ramos-Vara J, Scase TJ, Schulman FY, Sledge D, Smedley RC, Smith K, Snyder PW, Southorn E, Stedman NL, Steficek BA, Stromberg PC, Valli VE, Weisbrode SE, Yager J, Heller J, Miller R. 2011. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol 48:147-155.
56. Knapp DW. 2006. Animal models: naturally occurring canine urinary bladder cancer. In: Lerner SP, Schoenberg MP, Sternberg CN, eds. Textbook of Bladder Cancer. Oxon UK: Taylor and Francis. p 171-175.
57. Knapp DW, Adams LG, Degrand AM, Niles JD, Ramos-Vara JA, Weil AB, O'Donnell MA, Lucroy MD, Frangioni JV. 2007. Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. Eur Urol 52:1700-1708.
58. Knapp DW, Glickman NW, Denicola DB, Bonney PL, Lin TL, Glickman LT. 2000. Naturally-occurring canine transitional cell carcinoma of the urinary bladder: A relevant model of human invasive bladder cancer. Urol Oncol 5:47-59.
59. Knapp DW, Glickman NW, Widmer WR, DeNicola DB, Adams LG, Kuczek T, Bonney PL, DeGortari AE, Han C, Glickman LT. 2000. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 46:221-226.
60. Knapp DW, Henry CJ, Widmer WR, Tan KM, Moore GE, Ramos-Vara JA, Lucroy MD, Greenberg CB, Greene SN, Abbo AH, Hanson PD, Alva R, Bonney PL. 2013. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 27:126-133.
61. Knapp DW, McMillan SK. 2013. Tumors of the urinary system. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's Small Animal Clinical Oncology, 5th ed. St. Louis: Elsevier-Saunders. p 572-582.
62. Knapp DW, Peer WA, Conteh A, Diggs AR, Cooper BR, Glickman NW, Bonney PL, Stewart JC, Glickman LT, Murphy AS. 2013. Detection of herbicides in the urine of pet dogs following home lawn chemical application. Sci Total Environ 456-457:34-41.
63. KnappDW, Richardson RC, Bottoms GD, Teclaw R, Chan TC. 1992. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 29:214-218.
64. Knapp DW, Richardson RC, Chan TCK, Bottoms GD, Widmer WR, DeNicola DB, Teclaw R, Bonney PL, Kuczek T. 1994. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 8:273-278.
65. Koutros S, Lynch CF, Ma X, Lee WJ, Hoppin JA, Christensen CH, Andreotti G, Freeman LB, Rusiecki JA, Hou L, Sandler DP, Alavanja MC. 2009. Heterocyclic aromatic amine pesticide use and human cancer risk: Results from the U.S. Agricultural Health Study. Int J Cancer 124:1206-1212.
66. Ku JH, Godoy G, Amiel GE, Lerner SP. 2012. Urine survivin as a diagnostic biomarker for bladder cancer: A systematic review. BJU Int 110: 630-636.
67. Langner C, Ratschek M, Tsybrovskyy O, Schips L, Ziguener R. 2003. P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. J Histochem Cytochem 51:1097-1099.
68. Leach TN, Childress MO, Greene SN, Mohamed AS, Moore GE, Schrempp DR, Lahrman SR, Knapp DW. 2012. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. Vet Comp Oncol 10:102-112.
69. Lei AQ, Cheng L, Pan CX. 2011. Current treatment of metastatic bladder cancer and future directions. Expert Rev Anticancer Ther 11:1851-1862.
70. Lerner SP, Schoenberg MP, Sternberg CN. 2006. Textbook of Bladder Cancer. Oxon UK: Taylor and Francis.
71. Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM. 2012. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31:4759-4767.
72. Li Y, Izumi K, Miyamoto H. 2012. The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol 42:569-577.
73. Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. 2013. Lowdose metronomic chemotherapy: A systematic literature analysis. Eur J Cancer 49:3387-3395.
74. Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO Jr, de Vere White R, Pan CX. 2011. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol Cancer 10:9.
75. Low PS, HenneWA, Doorneweerd DD. 2008. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 41:120-129.
76. MacVicar GR, Hussain MH. 2013. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol 25:252-260.
77. Maximov PY, Lee TM, Jordan VC. 2013. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 8:135-155.
78. McCleary-Wheeler AL, Williams LE, Hess PR, Suter SE. 2010. Evaluation of an in vitro telomeric repeat amplification protocol assay to detect telomerase activity in canine urine. Am J Vet Res 71:1468-1474.
79. McMillan SK, Boria P, Moore GE, Widmer WR, Bonney PL, Knapp DW. 2011. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 239:1084-1089.
80. Meuten DJ, Meuten TLK. 2014. Tumors of the urinary system. In: Meuten D, ed. Tumors in Domestic Animals, 5th ed. Hoboken NJ: Wiley.
81. Miller RS, Torti FM. 1992. Chemotherapy of advanced transitional-cell carcinoma of the bladder. Cancer Chemother Pharmacol 30:S99-S110.
82. Mitra AP, Datar RH, Cote RJ. 2006. Molecular pathways in invasive bladder cancer: New insights into mechanisms, progression, and target identification. J Clin Oncol 24:5552-5564.
83. Mitra AP, Hansel DE, Cote RJ. 2012. Prognostic value of cell-cycle regulation biomarkers in bladder cancer. Semin Oncol 39:524-533.
84. Miyamoto H, Izumi K, Yao JL, Li Y, Yang Q, McMahon LA, Gonzalez-Roibon N, Hicks DG, Tacha D, Netto GJ. 2012. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Hum Pathol 43:2033-2040.
85. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C. 2007. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99: 558-568.
86. Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S. 2012. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109:1716-1726.
87. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL, Knapp DW. 2002. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 62:356-358.
88. Mohammed SI, Craig BA, Mutsaers AJ, Glickman NW, Snyder PW, deGortari AE, Schlittler DL, Coffman KT, Bonney PL, Knapp DW. 2003. Effects of the cyclooxygenase inhibitor, piroxicam in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2:183-188.
89. Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, Lu M, Wu L, Zheng R, Stewart J, Knapp DW. 2006. Cyclooxygenase inhibitors in urinary bladder cancer: In vitro and in vivo effects. Mol Cancer Ther 5:329-336.
90. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT. 1999. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59:5647-5650.
91. Mostofi K, Ito N, Weinstein R. 1986. Pathology: The need for standardization of pathological examination and reporting. In: Denis L, ed. Developments in Bladder Cancer. New York: Alan R. Liss. p 67-83.
92. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N. 2007. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 25:285-295.
93. Mutsaers AJ. 2009. Metronomic chemotherapy. Top Companion Anim Med 24:137-143.
94. Mutsaers AJ, Widmer WR, Knapp DW. 2003. Canine transitional cell carcinoma. J Vet Intern Med 17:136-144.
95. Nars MS, Kaneno R. 2013. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer 132:2471-2478.
96. Nolan MW, Kogan L, Griffin LR, Custis JT, Harmon JF, Biller BJ, Larue SM. 2012. Intensity-modulated and image-guided radiation therapy for treatment of genitourinary carcinomas in dogs. J Vet Intern Med 26:987-995.
97. Okajima E, Hiramatsu T, Hirao K, Ijuin M, Hirao Y, Babaya K, Ikuma S, Ohara S, Shiomi T, Hijioka T, Ohishi H. 1981. Urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in dogs. Cancer Res 41:1958-1966.
98. Orlando C, Gelmini S, Selli C, Pazzagli M. 2001. Telomerase in urological malignancy. J Urol 166:666-673.
99. Owen LN. 1980. TNM Classification of Tumours in Domestic Animals. Geneva: World Health Organization.
100. Parker HG, Shearin AL, Ostrander EA. 2010. Man's best friend becomes biology's best in show: Genome analyses in the domestic dog. Annu Rev Genet 44:309-336.
101. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. 2005. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284-293.
102. Patrick DJ, Fitzgerald SD, Sesterhenn A, Davis CJ, Kiupel M. 2006. Classification of canine urinary bladder urothelial tumours based on the World Health Organization/International Society of Urological Pathology consensus classification. J Comp Pathol 135:190-199.
103. Patronek GJ, Waters DJ, Glickman LT. 1997. Comparative longevity of pet dogs and humans: implications for gerontology research. J Gerontol A Biol Sci Med Sci 52:B171-B178.
104. Ploeg M, Aben KKH, Kiemeney LA. 2009. The present and future burden of urinary bladder cancer in the world. World J Urol 27:289-293.
105. Poirier VJ, Forrest LJ, Adams WM, Vail DM. 2004. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: A pilot study. J Am Anim Hosp Assoc 40:131-136.
106. Raghavan M, Knapp DW, Bonney PL, Dawson MH, Glickman LT. 2005. Evaluation of the effect of dietary vegetable consumption on reducing risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. J Am Vet Med Assoc 227:94-100.
107. Raghavan M, Knapp DW, Dawson MH, Bonney PL, Glickman LT. 2004. Topical flea and tick pesticides and the risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. J Am Vet Med Assoc 225:38-394.
108. Rahmani AH, Alzohairy M, Babiker AY, Khan AA, Aly SM, Rizvi MA. 2013. Implication of androgen receptor in urinary bladder cancer: A critical mini review. Int J Mol Epidemiol Genet 4:150-155.
109. Ramos-Vara JA, Miller MA, Boucher M, Roudabush A, Johnson GC. 2003. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors. Vet Pathol 40:55-62.
110. Rankin WV, Henry CJ, Turnquist SE, Turk JR, Beissenherz ME, Tyler JW, Rucker EB, Knapp DW, Rodriguez CO, Green JA. 2008. Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma. Vet Comp Oncol. 6:141-150.
111. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, Vetzel M, Kleindl P, Vlahov IR, Leamon CP. 2007. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 67:4434-4442.
112. Reed LT, Knapp DW, Miller MA. 2013. Cutaneous metastasis of transitional cell carcinoma in 12 dogs. Vet Pathol 50:676-681.
113. Roberts JT, von der Maase H, Sengeløv L, Conte PF, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. 2006. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 17:v118-v122.
114. Schrempp DR, Childress MO, Stewart JC, Leach TN, Tan KM, Abbo AH, de Gortari AE, Bonney PL, Knapp DW. 2013. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. J Am Vet Med Assoc 242:1534-1538.
115. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y. 2009. Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study. Clin Cancer Res 15:7012-7019.
116. Shirahama T. 2000. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6:2424-2430.
117. Singh BP, Nyska A, Kissling GE, Lieuallen W, Johansson SL, Malarkey DE, Hooth MJ. 2010. Urethral carcinoma and hyperplasia in male and female B6C3F1 mice treated with 3, 3', 4, 4'-tetrachloroazobenzene (TCAB). Toxicol Pathol 38:372-381.
118. Smee N, Loyd K, Grauer GF. 2013. UTIs in small animal patients: Part 2: Diagnosis, treatment, and complications. J Am Anim Hosp Assoc 49:83-94.
119. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. 1999. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 341:452-453.
120. Tanaka MF, Sonpavde G. 2011. Diagnosis and management of urothelial carcinoma of the bladder. Postgrad Med 123:43-55.
121. Thun MJ, Jacobs EJ, Patrono C. 2012. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9:259-267.
122. Torres de la Riva G, Hart BL, Farver TB, Oberbauer AM, Messam LL, Willits N, Hart LA. 2013. Neutering dogs: effects on joint disorders and cancers in golden retrievers. PLoS One 8:e55937.
123. Valli VE, Norris A, Jacobs RM, Laing E, Withrow S, Macy D, Tomlinson J, McCaw D, Ogilvie GK, Pidgeon G, Henderson RA. 1995. Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival. J Comp Pathol 113:113-130.
124. Veterinary Co-operative Oncology Group. 2004. Veterinary co-operative oncology group-Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2:194-213.
125. Vilar FO, de Araújo LA, Lima SV. 2004. Total bladder replacement with de-epithelialized ileum. Experimental study in dogs. Int Braz J Urol 30:237-244.
126. Villamil JA, Henry CJ, Hahn AW, Bryan JN, Tyler JW, Caldwell CW. 2009. Hormonal and sex impact on the epidemiology of canine lymphoma. J Cancer Epidemiol 2009:591753.
127. Wadhwa P, Goswami AK, Joshi K, Sharma SK. 2005. Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol 37:47-53.
128. Wallmeroth A, Wagner U, Moch H, Gasser TC, Sauter G, Mihatsch MJ. 1999. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. Urol Int 62:69-75.
129. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstätter A, Kronenberg F, Kiechl S. 2010. Telomere length and risk of incident cancer and cancer mortality. JAMA 304:69-75.
130. Wilson CR, Regnier FE, Knapp DW, Raskin RE, Andrews DA, Hooser SB. 2008. Glycoproteomic profiling of serum peptides in canine lymphoma and transitional cell carcinoma. Vet Comp Oncol 6:171-181.
131. Wu CT, Wu CF, Lu CH, Lin CC, Chen WC, Lin PY, Chen MF. 2011. Expression and function role of DNA methyltransferase 1 in human bladder cancer. Cancer 117:5221-5233.
132. Wu X, Kakehi Y, Taoka R, Tsunemori H, Inui M. 2005. Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J Urol 174:2138-2143.
133. Wu X, Kong XP, Pellicer A, Kreibich G, Sun TT. 2009. Uroplakins in urothelial biology, function, and disease. Kidney Int 75:1153-1165.
134. Wu X-R, Sun T-T, McConkey DJ, Shrader M, Papageorgiou A. 2006. Animal models of bladder cancer. In: Lerner SP, SchoenbergMP, Sternberg CN, eds. Textbook of Bladder Cancer. Oxon UK: Taylor and Francis. p 157-169.
135. Yagoda A. 1989. The role of cisplatin-based chemotherapy in advanced urothelial tract cancer. Semin Oncol 16:98-104.
136. Yi SW. 2013. Cancer incidence in Korean Vietnam veterans during 1992-2003: The Korean Veterans Health Study. J Prev Med Public Health 46:309-318.
137. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. 2012. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol 30:635-645.
138. Zhang J, Wei S, Liu L, Nagana Gowda GA, Bonney P, Stewart J, Knapp DW, Raftery D. 2012. NMR-based metabolomics study of canine bladder cancer. Biochim Biophys Acta 1822:1807-1814.
139. Zhao X, Li H, Lee RJ. 2008. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 5:309-319.